NCT07100054View on ClinicalTrials.gov

Pharmacogenomic and Circulating Biomarkers for CDK4/6 Inhibitors

Not yet recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
CDK4/6 InhibitorBreast CancerCYP3A4 Protein, HumanDrug InteractionPharmacogenetic Testing
Interventions
GENETIC

Whole gene sequencing

Whole gene sequencing of CYP3A4 and PXR

OTHER

Drug-drug interaction analysis

Evaluating potential drug interactions with CYP3A4 inhibitors and inducers

OTHER

Biomarker analysis

Determination of circulating CYP3A4 mRNA, and 4b-hydroxycholesterol

Trial Locations (1)

Unknown

London Health Sciences Centre Research Institute, London

All Listed Sponsors
lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER